Zevra to Participate at Upcoming Investor Conferences Feb 24, 2025 04:02PM
Zevra Therapeutics (ZVRA) Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C Nov 21, 2024 04:53PM
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C Nov 21, 2024 04:51PM
Zevra Therapeutics' (ZVRA) MIPLYFFA Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C Sep 20, 2024 12:08PM
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C Sep 20, 2024 12:08PM


Aug 7, 2024 09:34AM Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
Aug 2, 2024 05:50PM FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Jul 30, 2024 08:38AM Zevra Therapeutics to Report Second Quarter 2024 Financial Results
Apr 15, 2024 05:02PM Zevra Therapeutics (ZVRA) Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C
Apr 15, 2024 05:01PM Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Mar 28, 2024 04:32PM Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates